ICU kidney patients: do blood thinners need a new recipe?
NCT ID NCT07384598
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the blood thinner enoxaparin works in critically ill ICU patients with kidney failure, some on dialysis and some not. Researchers will measure drug levels in the blood over 24 hours after a daily shot. The goal is to see if current dosing is enough to prevent dangerous clots, since kidney problems can change how the drug is cleared from the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enoxaparin (a blood thinner)
- What this could lead to
- If successful, this could lead to better dosing guidelines for blood thinners in ICU patients with kidney problems, reducing clot risks.
- What could go wrong
- This is a small, early-stage observational study (60 people) that only measures drug levels, not actual outcomes like clot prevention. Results may not apply to all ICU patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RENAL FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may predict transfusion needs to shield ICU patients from organ failure
- Can a common gout pill shield hearts in kidney disease?
- A simple blood test trend may flag ICU patients at risk
- Could a simple CT scan reveal which ICU cancer patients are at highest risk?
- A gentle touch from family may calm the ICU storm
- Can we predict who sleeps poorly after heart surgery?